Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA).
Identifieur interne : 001453 ( PubMed/Corpus ); précédent : 001452; suivant : 001454Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA).
Auteurs : Maren Eggers ; Markus Eickmann ; Juergen ZornSource :
- Infectious diseases and therapy [ 2193-8229 ] ; 2015.
Abstract
Since the first case of Middle East Respiratory Syndrome coronavirus (MERS-CoV) infection was reported in 2012, the virus has infected more than 1300 individuals in 26 countries, and caused more than 480 deaths. Human-to-human transmission requires close contact, and has typically occurred in the healthcare setting. Improved global awareness, together with improved hygiene practices in healthcare facilities, has been highlighted as key strategies in controlling the spread of MERS-CoV. This study tested the in vitro efficacy of three formulations of povidone iodine (PVP-I: 4% PVP-I skin cleanser, 7.5% PVP-I surgical scrub, and 1% PVP-I gargle/mouthwash) against a reference virus (Modified vaccinia virus Ankara, MVA) and MERS-CoV.
DOI: 10.1007/s40121-015-0091-9
PubMed: 26416214
Links to Exploration step
pubmed:26416214Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA).</title><author><name sortKey="Eggers, Maren" sort="Eggers, Maren" uniqKey="Eggers M" first="Maren" last="Eggers">Maren Eggers</name><affiliation><nlm:affiliation>Labor Prof. Gisela Enders MVZ GbR and the Institute of Virology, Infectious Diseases and Epidemiology e.V., Stuttgart, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Eickmann, Markus" sort="Eickmann, Markus" uniqKey="Eickmann M" first="Markus" last="Eickmann">Markus Eickmann</name><affiliation><nlm:affiliation>Institute for Virology, Philipps University of Marburg, Marburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Zorn, Juergen" sort="Zorn, Juergen" uniqKey="Zorn J" first="Juergen" last="Zorn">Juergen Zorn</name><affiliation><nlm:affiliation>Mundipharma Research GmbH & Co.KG, Limburg, Germany. Juergen.zorn@mundipharma-rd.eu.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26416214</idno><idno type="pmid">26416214</idno><idno type="doi">10.1007/s40121-015-0091-9</idno><idno type="wicri:Area/PubMed/Corpus">001453</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001453</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA).</title><author><name sortKey="Eggers, Maren" sort="Eggers, Maren" uniqKey="Eggers M" first="Maren" last="Eggers">Maren Eggers</name><affiliation><nlm:affiliation>Labor Prof. Gisela Enders MVZ GbR and the Institute of Virology, Infectious Diseases and Epidemiology e.V., Stuttgart, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Eickmann, Markus" sort="Eickmann, Markus" uniqKey="Eickmann M" first="Markus" last="Eickmann">Markus Eickmann</name><affiliation><nlm:affiliation>Institute for Virology, Philipps University of Marburg, Marburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Zorn, Juergen" sort="Zorn, Juergen" uniqKey="Zorn J" first="Juergen" last="Zorn">Juergen Zorn</name><affiliation><nlm:affiliation>Mundipharma Research GmbH & Co.KG, Limburg, Germany. Juergen.zorn@mundipharma-rd.eu.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Infectious diseases and therapy</title><idno type="ISSN">2193-8229</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Since the first case of Middle East Respiratory Syndrome coronavirus (MERS-CoV) infection was reported in 2012, the virus has infected more than 1300 individuals in 26 countries, and caused more than 480 deaths. Human-to-human transmission requires close contact, and has typically occurred in the healthcare setting. Improved global awareness, together with improved hygiene practices in healthcare facilities, has been highlighted as key strategies in controlling the spread of MERS-CoV. This study tested the in vitro efficacy of three formulations of povidone iodine (PVP-I: 4% PVP-I skin cleanser, 7.5% PVP-I surgical scrub, and 1% PVP-I gargle/mouthwash) against a reference virus (Modified vaccinia virus Ankara, MVA) and MERS-CoV.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">26416214</PMID><DateCompleted><Year>2015</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2193-8229</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Infectious diseases and therapy</Title><ISOAbbreviation>Infect Dis Ther</ISOAbbreviation></Journal><ArticleTitle>Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA).</ArticleTitle><Pagination><MedlinePgn>491-501</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40121-015-0091-9</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Since the first case of Middle East Respiratory Syndrome coronavirus (MERS-CoV) infection was reported in 2012, the virus has infected more than 1300 individuals in 26 countries, and caused more than 480 deaths. Human-to-human transmission requires close contact, and has typically occurred in the healthcare setting. Improved global awareness, together with improved hygiene practices in healthcare facilities, has been highlighted as key strategies in controlling the spread of MERS-CoV. This study tested the in vitro efficacy of three formulations of povidone iodine (PVP-I: 4% PVP-I skin cleanser, 7.5% PVP-I surgical scrub, and 1% PVP-I gargle/mouthwash) against a reference virus (Modified vaccinia virus Ankara, MVA) and MERS-CoV.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">According to EN14476, a standard suspension test was used to assess virucidal activity against MVA and large volume plating was used for MERS-CoV. All products were tested under clean (0.3 g/L bovine serum albumin, BSA) and dirty conditions (3.0 g/L BSA + 3.0 mL/L erythrocytes), with application times of 15, 30, and 60 s for MVA, and 15 s for MERS-CoV. The products were tested undiluted, 1:10 and 1:100 diluted against MVA, and undiluted against MERS-CoV.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A reduction in virus titer of ≥4 log10 (corresponding to an inactivation of ≥99.99%) was regarded as evidence of virucidal activity. This was achieved versus MVA and MERS-CoV, under both clean and dirty conditions, within 15 s of application of each undiluted PVP-I product.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These data indicate that PVP-I-based hand wash products for potentially contaminated skin, and PVP-I gargle/mouthwash for reduction of viral load in the oral cavity and the oropharynx, may help to support hygiene measures to prevent transmission of MERS-CoV.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Mundipharma Research GmbH & Co.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eggers</LastName><ForeName>Maren</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Labor Prof. Gisela Enders MVZ GbR and the Institute of Virology, Infectious Diseases and Epidemiology e.V., Stuttgart, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eickmann</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Virology, Philipps University of Marburg, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zorn</LastName><ForeName>Juergen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Mundipharma Research GmbH & Co.KG, Limburg, Germany. Juergen.zorn@mundipharma-rd.eu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Infect Dis Ther</MedlineTA><NlmUniqueID>101634499</NlmUniqueID><ISSNLinking>2193-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enveloped virus</Keyword><Keyword MajorTopicYN="N">Gargle</Keyword><Keyword MajorTopicYN="N">Hand hygiene</Keyword><Keyword MajorTopicYN="N">MERS-CoV</Keyword><Keyword MajorTopicYN="N">MVA</Keyword><Keyword MajorTopicYN="N">Middle East respiratory syndrome coronavirus</Keyword><Keyword MajorTopicYN="N">Modified vaccinia virus Ankara</Keyword><Keyword MajorTopicYN="N">Mouthwash</Keyword><Keyword MajorTopicYN="N">Povidone iodine</Keyword><Keyword MajorTopicYN="N">Virucidal</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>09</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26416214</ArticleId><ArticleId IdType="doi">10.1007/s40121-015-0091-9</ArticleId><ArticleId IdType="pii">10.1007/s40121-015-0091-9</ArticleId><ArticleId IdType="pmc">PMC4675768</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vaccine. 2001 Jun 14;19(27):3700-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11395204</ArticleId></ArticleIdList></Reference><Reference><Citation>Dermatology. 2006;212 Suppl 1:119-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16490989</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hosp Infect. 2008 Feb;68(2):159-63</Citation><ArticleIdList><ArticleId IdType="pubmed">18207605</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hosp Infect. 2012 Dec;82(4):277-80</Citation><ArticleIdList><ArticleId IdType="pubmed">23009803</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference><Reference><Citation>Indian Pediatr. 2013 Oct;50(10):917-21</Citation><ArticleIdList><ArticleId IdType="pubmed">23585422</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2013 Dec;85(12):2151-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23959825</ArticleId></ArticleIdList></Reference><Reference><Citation>Saudi Dent J. 2009 Oct;21(3):127-33</Citation><ArticleIdList><ArticleId IdType="pubmed">23960471</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Curr. 2013 Nov 12;5:</Citation><ArticleIdList><ArticleId IdType="pubmed">24270606</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2015 Mar 06;7(3):996-1019</Citation><ArticleIdList><ArticleId IdType="pubmed">25757061</ArticleId></ArticleIdList></Reference><Reference><Citation>Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Apr;58(4-5):491-2</Citation><ArticleIdList><ArticleId IdType="pubmed">25893885</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2015 Sep 17;15:375</Citation><ArticleIdList><ArticleId IdType="pubmed">26381737</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull World Health Organ. 1972;46(6):729-34</Citation><ArticleIdList><ArticleId IdType="pubmed">4538534</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001453 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001453 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26416214
|texte= Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26416214" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |